Physician profile
Jill E Glick
NPI 1851351589
$7,562.15
in general payments reported to CMS, 2019-2025
44 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $346 · 2021: $883 · 2022: $899 · 2023: $1,271 · 2024: $1,060 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,408.79 | 2019-2025 | |
| Novo Nordisk INC | $884.62 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic Minimed, INC. | $866.78 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $408.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $384.69 | 2019-2022 | |
| Astellas Pharma US INC | $374.29 | 2022-2025 | Veozah |
| Pfizer INC. | $366.25 | 2019-2025 | |
| Lilly USA, LLC | $321.92 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $210.49 | 2021-2024 | Rexulti |
| Halozyme INC | $182.54 | 2023 | |
| Sanofi-Aventis U.S. LLC | $177.69 | 2021-2025 | |
| Glaxosmithkline, LLC. | $176.99 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $165.08 | 2019-2025 | Evenity, Prolia, Prolia |
| Dexcom, INC. | $121.34 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $112.35 | 2022-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.